Table 4.
World Health Organization/European Organization for Research and Treatment of Cancer staging of mycosis fungoides/Sézary syndrome
| Stage | T | N | M | B |
|---|---|---|---|---|
| IA | 1.0 | 0 | 0 | 0.1 |
| IB | 2.0 | 0 | 0 | 0.1 |
| II | 1.2 | 1.2 | 0 | 0.1 |
| IIB | 3.0 | 0–2 | 0 | 0.1 |
| IIIA | 4.0 | 0–2 | 0 | 0 |
| IIIB | 4.0 | 0–2 | 0 | 1.0 |
| IVA1 | 1–4 | 0–2 | 0 | 2.0 |
| IVA2 | 1–4 | 3.0 | 0 | 0–2 |
| IVB | 1–4 | 0–3 | 1 | 0–2 |
Republished with permission of American Society of Hematology, from Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110(6):1715; permission conveyed through Copyright Clearance Center, Inc.